Search Results

You searched for: rituximab

SMC Advice

  • obinutuzumab (Gazyvaro)
    SMC Drug ID: 1219/17; Manufacturer: Roche; Indication: In combination with bendamustine followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with rituximab or a rituximab-containing regimen.; Submission Type: Full submission; Status: Accepted; Date Advice Published:  13/03/2017;
  • bortezomib (Velcade)
    SMC Drug ID: 1075/15; Manufacturer: Janssen-Cilag Ltd; Indication: In combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation; Submission Type: Full submission; Status: Accepted; Date Advice Published:  07/09/2015;
  • idelalisib (Zydelig)
    SMC Drug ID: 1026/15; Manufacturer: Gilead Sciences Ltd; Indication: In combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL): • who have received at least one prior therapy, or • as first line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.; Submission Type: Full submission; Status: Restricted; Date Advice Published:  09/03/2015;
  • rituximab subcutaneous (Mabthera)
    SMC Drug ID: 975/14; Manufacturer: Roche; Indication: For non-Hodgkin’s lymphoma (NHL) in adults: - previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy; - maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy; - treatment of patients with CD20 positive diffuse large B cell - non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.; Submission Type: Full submission; Status: Restricted; Date Advice Published:  07/07/2014;
  • rituximab (Mabthera)
    SMC Drug ID: 894/13; Manufacturer: Roche; Indication: In combination with glucocorticoids for the induction of remission in adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).; Submission Type: Full submission; Status: Restricted; Date Advice Published:  09/09/2013;

More results from the SMC Advice section

Forthcoming Submissions

About SMC

  • SMC Minutes - Tuesday, 3 October 2006
    Minutes of the SMC Meeting held on Tuesday 3 October 2006 NHS Quality Improvement Scotland, Delta House, 50 West Nile Street, Glasgow G1 2NP Present: Professor David Webb (Chairman); Professor James ...
  • SMC Minutes 5th July 2011
    Minutes of the SMC Meeting held on Tuesday 05 July 2011 Healthcare Improvement Scotland, Delta House, 50 West Nile Street, Glasgow, G1 2NP Present:  Ms Angela Timoney (Chairman), Ms Sandra Auld, ...
  • SMC Minutes Tuesday 7 September 2010
    Minutes of the SMC Meeting held on Tuesday 07 September 2010 NHS Quality Improvement Scotland, Delta House, 50 West Nile Street, Glasgow, G1 2NP Present:  Ms Angela Timoney (Chairman), Mrs Laura ...
  • SMC Minutes: Tuesday 2 November 2010
    Minutes of the SMC Meeting held on Tuesday 02 November 2010 NHS Quality Improvement Scotland, Delta House, 50 West Nile Street, Glasgow, G1 2NP Present:  Professor Ken Paterson (Chairman), Dr Ke...
  • Minutes of the SMC Meeting held on Tuesday 4 August 2009
    Minutes of the SMC Meeting held on Tuesday 4 August 2009 NHS Quality Improvement Scotland, Delta House, 50 West Nile Street, Glasgow, G1 2NP Present: Professor Ken Paterson (Chairman), Mrs Laura Ace...

More results from the About SMC section

Help on how to improve your search.